Table 2.

HSV-2 vaccine candidates in preclinical development

Candidate	Platform	Antigenic Targets	Immune Response	Results in animal models
THV	Trivalent subunit	gD, gC, gE	Neutralizing Abs	Prophylactic in mice and guinea pigs Decreased shedding in guinea pigs
ΔgD-2	gD null Single cycle	Multiple targets excluding gD	FcγR-activating Abs CD4, CD8 responses Passive protection	100% protection against HSV-1 and HSV-2 clinical isolates in male and female mice with multiple challenge routes; Prevents establishment of latency Passive protection
gD27	gD-nectin binding impaired; Live attenuated	Multiple	Neutralizing Abs	Improved protection compared to gD-2 subunit
VC2	Deleted in gK and UL20 Defective in establishing latency; replication competent	Multiple	Neutralizing Abs T cell memory (gB, gD) TFH and Th17 responses	100% protection in mice intravaginally challenged with HSV-1(McKrae) or HSV-2(G) Prevents latency